Expression of the matrix-degrading enzyme, aggrecanase, ADAMTS5, was reduced by both ERT and combined treatment, while the apoptosis marker, PARP, which is elevated in chondrocytes from MPS VI rats [15], was only reduced by the combined treatment protocol. Here, ELF3 is linked to mucopolysaccharidosis type 6.